The Latin Bible as Codex

The University of Pennsylvania Libraries A.S.W. Rosenbach Lectures in Bibliography for 2008 The Latin Bible as Codex Paul Saenger, The Newberry Library, Chicago, Illinois April 14, 15, and 17, 2008 5:30PM Rosenwald Gallery, 6th floor Van Pelt-Dietrich Library University of Pennsylvania 3420 Walnut Street Philadelphia PA 19104-6206 Monday, April 14, 2008: Christian Versification Tuesday, April 15, 2008: The Birth of Modern Chapters Thursday, April 17, 2008: The Printed Codex The distinguished scholar of medieval reading practices Paul Saenger presents three lectures on the development of the medieval and early printed Bible. Co-editor of the 1999 The Bible as Book: The First Printed Editions, Dr. Saenger has also published Space Between Words: The Origins of Silent Reading (1997) and the Catalogue of the Pre-1500 Western Manuscript Books at the Newberry Library (1989)

Long acting growth hormone (LAGH), an update

In 1957, Maurice Raben at Yale was able to isolate and purify growth hormone from cadaveric pituitary glands. Pituitary growth hormone was the only way to treat children with growth hormone (GH) deficiency, until 1985 when recombinant GH became available for daily subcutaneous injection. For many years, the pediatric endocrine community longed for a long-acting recombinant GH formulation that would decrease the inconvenience of daily injections. Several mechanisms were employed to develop a GH that is rapidly absorbed into the blood stream after subcutaneous injection, but provides slow removal from the circulatory system to potentially optimize patient adherence to GH therapy. Four long-acting growth hormones are currently available in the world, or are close to regulatory approval. They are: (1) Pegylated formulations, (2) Prodrug formulations which are converted into active drug, (3) Nonvalent transient albumin binding GH compounds and (4) GH fusion proteins where a protein si fused with GH. All four formulations have undergone detailed phase 3 studies and were found to show non-inferiority in these clinical studies. All four demonstrate a safety and tolerability profile that is comparable to that of daily somatropin with an excellent adherence profile

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109905/1/cptclpt19923.pd

Low Temperature Effects on the Mechanical, Fracture, and Dynamic Behavior of Carbon and E-glass Epoxy Laminates

An experimental investigation through which the effects of low temperatures on the mechanical, fracture, impact, and dynamic properties of carbon- and E-glass-epoxy composite materials has been conducted. The objective of the study is to quantify the influence of temperatures from 20 °C down to −2 °C on the in-plane (tensile/compressive) and shear material properties, static and dynamic Mode-I fracture characteristics, impact/residual strength, and the storage and loss moduli for the materials considered. The low end of the temperature range considered in the study is associated with Arctic seawater as well as conditions found at extreme ocean depths (2 °C–4 °C). In the investigation, both carbon/epoxy and E-glass/epoxy laminates are evaluated as these materials are of keen interest to the marine and undersea vehicle community. The mechanical characterization of the laminates consists of controlled tension, compression, and short beam shear testing. The Mode-I fracture performance is quantified under both quasi-static and highly dynamic loading rates with additional flexure after impact strength characterization conducted through the use of a drop tower facility. Finally, dynamic mechanical analysis (DMA) testing has been completed on each material to measure the storage and loss moduli of the carbon fiber- and E-glass fiber reinforced composites. The findings of the study show that nearly all characteristics of the mechanical performance of the laminates are both material and temperature dependent

Comparison of urinary 6‐β‐cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110077/1/cptclpt1992140.pd

Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: Educational recommendations from the IFCC committee on clinical application of cardiac bio-markers

The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides evidence-based educational documents to facilitate uniform interpretation and utilization of cardiac biomarkers in clinical laboratories and practice. The committee’s goals are to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay in clinical practice. Measurement of high-sensitivity cardiac troponin (hs-cTn) assays is a cornerstone in the clinical evaluation of patients with symptoms and/or signs of acute cardiac ischemia. To define myocardial infarction, the Universal Definition of Myocardial Infarction requires patients who manifest with features suggestive of acute myocardial ischemia to have at least one cTn concentration above the sex-specific 99th percentile upper reference limit (URL) for hs-cTn assays and a dynamic pattern of cTn concentrations to fulfill the diagnostic criteria for MI. This special report provides an overview of how hs-cTn 99th percentile URLs should be established, including recommendations about prescreening and the number of individuals required in the reference cohort, how statistical analysis should be conducted, optimal preanalytical and analytical protocols, and analytical/biological interferences or confounds that can affect accurate determination of the 99th percentile URLs. This document also provides guidance and solutions to many of the issues posed.publishedVersio

Results of a Second Year of Therapy with the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty

Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The histrelin subcutaneous implant is safe and effective in the treatment of CPP for one year. Objective. The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment. Methods. A prospective one-year study following an initial 12-month treatment period was conducted. Results. Thirty-one patients (29 girls) aged 7.7 ± 1.5 years received a second implant. Eighteen were naïve to GnRHa therapy at first implantation. Peak LH declined from 0.92 ± 0.58 mIU/mL at 12 months to 0.51 ± 0.33 mIU/mL at 24 months (P < .0001) in naïve subjects, and from 0.74 ± 0.50 mIU/mL at 12 months to 0.45 ± 0.35 mIU/mL at 24 months (P = .0081) in previously treated subjects. Predicted adult height increased by 5.1 cm at 24 months (P = .0001). Minor implant site reactions occurred in 61%, while minor difficulties with explantation occurred in 32.2% of subjects. Conclusion. The histrelin implant demonstrates profound hypothalamic-pituitary-gonadal axis suppression when a new implant is placed for a second year of treatment. Prospective follow-up of this therapeutic modality for the treatment of CPP is needed

Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program

Growth hormone (GH) is used to treat short stature and growth failure associated with growth disorders. Birth size and GH status variably modulate response to GH therapy. The aim of this study was to determine the effect of birth size on response to GH therapy, and to determine the impact of GH status in patients born small for gestational age (SGA) on response to GH therapy. Data from the prospective, non-interventional American Norditropin Studies: Web-Enabled Research (ANSWER) Program was analyzed for several growth outcomes in response to GH therapy over 3 years. GH-naïve children from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL (20 mIU/L), SGA with peak GH <10 ng/mL (20 mIU/L), isolated growth hormone deficiency (IGHD) born SGA, IGHD not born SGA and idiopathic short stature. For patients with IGHD, those who did not meet criteria for SGA at birth showed greater improvements in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth. For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike previous guidelines, we recommend that GH status be established in patients born SGA to optimize GH therapy